Our companies

Empowering change through science

We are full life cycle investors supporting scientists and entrepreneurs at any stage where we identify opportunity, from academic programs in need of industry sponsorship all the way to mature publicly traded companies.

Alcyone Therapeutics

Pioneering next-generation precision gene-based therapies for complicated disorders of the central nervous system (CNS). We integrate innovations in neuroscience, gene therapy, precision dosing and delivery, and manufacturing to deliver transformative therapies to patients.

Disease/TX area
Rare Disease, CNS
Ancora Heart

A medical device company dedicated to providing new treatment options for people with heart failure (HF). The company’s proprietary AccuCinch® Ventricular Restoration System is the first completely percutaneous device designed to restore the enlarged left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure.

Disease/TX area
Cardiovascular
Armo BioSciences

An immuno-oncology company with a pipeline of novel interleukins for cancer.

Disease/TX area
Cancer
Avidity Biosciences

We are delivering a new class of RNA therapeutics - AOCs - which combine the specificity of monoclonal antibodies and the precision of oligonucleotides. Through integrating these proven technologies, our AOC platform is able to deliver to previously inaccessible tissue and cell types and more effectively target the underlying genetic drivers of diseases. With an agile and diverse team, we are advancing and expanding our pipeline programs to offer treatment options for patients and their families.

Disease/TX area
Myotonic Dystrophy
Beta Bionics

The developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.

Disease/TX area
Type 1 Diabetes
CinCor Pharma

A clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, baxdrostat (CIN-107), for the treatment of hypertension and other cardio-renal diseases. It is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland.

Disease/TX area
Cardiovascular
Encoded

Developing life-changing therapeutics for severe genetic disorders that are not addressable with existing gene therapy approaches.

GH Research

A clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Disease/TX area
Neurology
Immunocore Holdings PLC

A London-based company with an immuno-oncology platform technology called ImmTACs. ImmTACs enable the potent targeting of intracellular cancer antigens with controlled pharmacology.

Disease/TX area
Cancer, Autoimmune, Infection
JiXing

Backed by RTW Investments, JiXing is a privately held, leading Shanghai-based biotechnology company committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.

Disease/TX area
Cardiovascular, Ophthalmology
Founded
2020
Magnolia Medical Technologies

Developing, manufacturing, and marketing innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests. Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT™) and Device (ISDD®) for blood culture collection and contamination prevention.

Disease/TX area
Inflammatory, Sepsis
Milestone Pharmaceuticals Inc

A late-stage biopharmaceutical company developing a drug intended to provide outpatient treatment of paroxysmal supraventricular tachycardia (PSVT).

Disease/TX area
Cardiovascular
NiKang

A preclinical stage biotech company discovering and developing innovative small molecule oncology medicines.

Disease/TX area
Oncology
Orchestra BioMed

The developer of Virtue SEB, a sirolimus eluting balloon for treatment of coronary and peripheral arterial disease.

Disease/TX area
Cardiovascular
Prometheus Biosciences Inc

Discovering and developing novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD).

Disease/TX area
IBD
Rocket Pharmaceuticals Inc

Bringing hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.

Disease/TX area
Rare pediatric diseases
Founded
2015
Tarsus

Focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions such as Demodex blepharitis.

Disease/TX area
Ophthalmology
Tenaya

A biotechnology company with a mission to discover, develop, and deliver curative therapies that address the underlying causes of heart disease.

Disease/TX area
Cardiovascular
Umoja Biopharma

Developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

Disease/TX area
Oncology
Ventyx

Advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with inflammatory and autoimmune diseases.

Disease/TX area
Inflammatory, Autoimmune
Visus

A clinical-stage pharmaceutical company developing presbyopia-correcting eye drop.

Disease/TX area
Ophthalmology
Yarrow

Yarrow is an RTW-incubated biotechnology company focused on developing therapeutics for auto-immune diseases.

Disease/TX area
CNS
Founded
2021

Rod dug in our company when many other investors disappeared. He did the work and realized BioCryst’s potential for treating rare diseases such as HAE long before others did.

Jon Stonehouse
Jon Stonehouse
CEO, BioCryst

RTW does deeper diligence than nearly any other investor I know. RTW’s research and guidance in the early days of Rainbow and noninvasive hemoglobin was a valuable resource. They helped us understand the opportunity and have been a trusted partner since.

Joe Kiani
Joe Kiani
Founder, Chairman, & CEO, Masimo

The RTW Team spotted the argenx investment opportunity ahead of the curve and rapidly developed from an investor to a loyal partner. Their data based approach and desire to understand resonates very well with our company culture.

Tim Van Hauwermeiren
Tim Van Hauwermeiren
CEO, Argenx

We view the team at RTW with highest regard. They believed in Alnylam's potential when the rest of the world was skeptical.

John Maraganore, PhD
John Maraganore, PhD
Founding CEO, Alnylam Pharmaceuticals

RTW uses scientific and clinical acumen to decipher critical investments. Rod and Piratip were excellent strategic partners who had the foresight to invest in Avexis.

Sukumar Nagendran, MD
Sukumar Nagendran, MD
Chief Medical Officer, Avexis

Rod and the team at RTW dug deep into our science, saw our potential early and share our drive to bring science to patients. As a member of our board, Rod’s wisdom and guidance has been invaluable. RTW is more than an investor, they are a true partner.

Sarah Boyce
President and CEO, Avidity

RTW is a very insightful and strategic investment firm. They had the foresight to invest in PTC after our acquisition of Emflaza and have spent a significant amount of time and effort to understand the potential of our pipeline.

Stu Peltz
Stu Peltz
CEO, PTC Therapeutics

RTW is among the most thoughtful and diligent teams we have encountered. They saw the commercial potential of MACI early on, and have been a tremendous partner to Vericel during a period of rapid growth for the company.

Nick Colangelo
Nick Colangelo
CEO, Vericel

RTW really took the time to understand our business, and they understood that the reasons that other people had said no were actually the very reasons to say yes. They backed us early and made good on their promise to be a true partner long after Establishment Labs' IPO. They are the entrepreneur's investor and a real value add.

Nick Lewin
Nick Lewin
Chairman, Establishment Labs

RTW’s passion for science and rational approach toward therapeutics development have been essential to the RCKT story. Rod and team have an uncanny ability to identify opportunities that no one else has, well ahead of the curve, and the rigorous discipline to water them gently. We value them highly as top shareholders, as founders and integral members of the Board, and most importantly as friends.

Gaurav Shah, MD
Gaurav Shah, MD
CEO, Rocket Pharmaceuticals

The RTW team did deep commercial diligence into the potential for a prophylactic HAE medicine well before other investors. Combined with their deep understanding of science, RTW was a terrific long-term shareholder, as we advanced DX-2930 through the clinic and sought to bring this important therapy to patients.

George Migausky
George Migausky
CFO, Dyax

The investments listed above include RTW funds’ investments in private companies that have had a liquidity event, or are investments of RTW Biotech Opportunities, Ltd. They do not include names of investments for which RTW is under non-disclosure obligations or in certain circumstances that are related to the protection of RTW’s competitive edge.

The discussion is included for informational purposes only and is intended to be illustrative but is not representative of transactions of a given type in which RTW may invest on behalf of the Funds. There can be no assurance that the Funds will achieve comparable results.

The above testimonials were given by CEOs or other senior executives of companies in which RTW has made an equity investment on behalf of managed funds. No compensation was provided to the individuals giving the testimonials. Joe Kiani and Guarav Shah are also investors in RTW managed funds. Stu Peltz is also a director of the board of Health Sciences Acquisitions Corporation 2, a SPAC sponsored by RTW Investments, LP, for which he has received stock grants in exchange for his service as a director. Since January 2022 John Maraganore has been an advisor to RTW Investments, LP, serving as Executive Partner.